This Medudy course is a video tutorial for physicians on the topic of “PSA response to darolutamide treatment.”
Prof. Dr. Christian Gratzke, Director of the Department of Urology at the University Medical Center Freiburg, presents new data on PSA response to darolutamide, specifically the post-hoc analysis of the ARASENS study on triple therapy for metastatic hormone-sensitive prostate cancer.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The course was developed with the kind support of Bayer.
At the end of this training you will know:
- the clinical relevance of PSA response to darolutamide in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
- the key findings of the post-hoc analysis of the ARASENS study on darolutamide triple therapy for mHSPC.
- den Zusammenhang zwischen dem Baseline-PSA-Wert und dem Erreichen eines nicht nachweisbaren PSA-Werts (<0,20 ng/mL) unter Darolutamid-Triple-Therapie. – die prognostische Bedeutung des Baseline-PSA-Werts für die Zeit bis zur PSA-Progression und zum Auftreten eines kastrationsresistenten Prostatakarzinoms (CRPC) in der ARASENS-Studie.
